Literature DB >> 25820773

T1ρ imaging in premanifest Huntington disease reveals changes associated with disease progression.

Shafik N Wassef1,2, John Wemmie3,4,5, Casey P Johnson1, Hans Johnson2, Jane S Paulsen3,6,7, Jeffrey D Long3,8, Vincent A Magnotta1,3,9.   

Abstract

BACKGROUND: Imaging biomarkers sensitive to Huntington's disease (HD) during the premanifest phase preceding motor diagnosis may accelerate identification and evaluation of potential therapies. For this purpose, quantitative MRI sensitive to tissue microstructure and metabolism may hold great potential. We investigated the potential value of T1ρ relaxation to detect pathological changes in premanifest HD (preHD) relative to other quantitative relaxation parameters.
METHODS: Quantitative MR parametric mapping was used to assess differences between 50 preHD subjects and 26 age- and sex-matched controls. Subjects with preHD were classified into two progression groups based on their CAG-age product (CAP) score; a high and a low/moderate CAP group. Voxel-wise and region-of-interest analyses were used to assess changes in the quantitative relaxation times.
RESULTS: T1ρ showed a significant increase in the relaxation times in the high-CAP group, as compared to controls, largely in the striatum. The T1ρ changes in the preHD subjects showed a significant relationship with CAP score. No significant changes in T2 or T2* relaxation times were found in the striatum. T2* relaxation changes were found in the globus pallidus, but no significant changes with disease progression were found.
CONCLUSION: These data suggest that quantitative T1ρ mapping may provide a useful marker for assessing disease progression in HD. The absence of T2 changes suggests that the T1ρ abnormalities are unlikely owing to altered water content or tissue structure. The established sensitivity of T1ρ to pH and glucose suggests that these factors are altered in HD perhaps owing to abnormal mitochondrial function.
© 2015 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  T1rho; imaging biomarkers; magnetic resonance imaging; premanifest Huntington disease; quantitative imaging

Mesh:

Substances:

Year:  2015        PMID: 25820773      PMCID: PMC4751081          DOI: 10.1002/mds.26203

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  50 in total

1.  Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.

Authors:  Sarah J Tabrizi; Ralf Reilmann; Raymund A C Roos; Alexandra Durr; Blair Leavitt; Gail Owen; Rebecca Jones; Hans Johnson; David Craufurd; Stephen L Hicks; Christopher Kennard; Bernhard Landwehrmeyer; Julie C Stout; Beth Borowsky; Rachael I Scahill; Chris Frost; Douglas R Langbehn
Journal:  Lancet Neurol       Date:  2011-12-02       Impact factor: 44.182

Review 2.  Development of biomarkers for Huntington's disease.

Authors:  David W Weir; Aaron Sturrock; Blair R Leavitt
Journal:  Lancet Neurol       Date:  2011-06       Impact factor: 44.182

3.  Disruption of response inhibition circuits in prodromal Huntington disease.

Authors:  Julia A Rao; Deborah L Harrington; Sally Durgerian; Christine Reece; Lyla Mourany; Katherine Koenig; Mark J Lowe; Vincent A Magnotta; Jeffrey D Long; Hans J Johnson; Jane S Paulsen; Stephen M Rao
Journal:  Cortex       Date:  2014-06-02       Impact factor: 4.027

4.  MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease.

Authors:  G Bartzokis; T A Tishler
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2000-06       Impact factor: 1.770

5.  Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia.

Authors:  S E Browne; A C Bowling; U MacGarvey; M J Baik; S C Berger; M M Muqit; E D Bird; M F Beal
Journal:  Ann Neurol       Date:  1997-05       Impact factor: 10.422

6.  Elevated brain iron is independent from atrophy in Huntington's Disease.

Authors:  Eve M Dumas; Maarten J Versluis; Simon J A van den Bogaard; Matthias J P van Osch; Ellen P Hart; Willeke M C van Roon-Mom; Mark A van Buchem; Andrew G Webb; Jeroen van der Grond; Raymund A C Roos
Journal:  Neuroimage       Date:  2012-03-28       Impact factor: 6.556

7.  Seeking Huntington disease biomarkers by multimodal, cross-sectional basal ganglia imaging.

Authors:  Cristina Sánchez-Castañeda; Andrea Cherubini; Francesca Elifani; Patrice Péran; Sara Orobello; Giovanni Capelli; Umberto Sabatini; Ferdinando Squitieri
Journal:  Hum Brain Mapp       Date:  2012-02-22       Impact factor: 5.038

8.  Functional magnetic resonance imaging of working memory in Huntington's disease: cross-sectional data from the IMAGE-HD study.

Authors:  Nellie Georgiou-Karistianis; Julie C Stout; Juan F Domínguez D; Sarah P Carron; Ayaka Ando; Andrew Churchyard; Phyllis Chua; India Bohanna; Alicia R Dymowski; Govinda Poudel; Gary F Egan
Journal:  Hum Brain Mapp       Date:  2013-08-02       Impact factor: 5.038

Review 9.  FSL.

Authors:  Mark Jenkinson; Christian F Beckmann; Timothy E J Behrens; Mark W Woolrich; Stephen M Smith
Journal:  Neuroimage       Date:  2011-09-16       Impact factor: 6.556

Review 10.  MRI biomarkers in Huntington's disease.

Authors:  Simon van den Bogaard; Eve Dumas; Jeroen van der Grond; Mark van Buchem; Raymund Roos
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01
View more
  9 in total

1.  Huntington disease: cerebrospinal fluid and MRI biomarkers for prodromal HD.

Authors:  Alex Chase
Journal:  Nat Rev Neurol       Date:  2015-04-21       Impact factor: 42.937

2.  Three-Dimensional GRE T mapping of the brain using tailored variable flip-angle scheduling.

Authors:  Casey P Johnson; Daniel R Thedens; Stanley J Kruger; Vincent A Magnotta
Journal:  Magn Reson Med       Date:  2020-02-12       Impact factor: 4.668

3.  COX REGRESSION WITH EXCLUSION FREQUENCY-BASED WEIGHTS TO IDENTIFY NEUROIMAGING MARKERS RELEVANT TO HUNTINGTON'S DISEASE ONSET.

Authors:  Tanya P Garcia; Samuel Müller
Journal:  Ann Appl Stat       Date:  2017-01-05       Impact factor: 2.083

4.  R1ρ sensitivity to pH and other compounds at clinically accessible spin-lock fields in the presence of proteins.

Authors:  Nana Owusu; Casey P Johnson; William Kearney; Dan Thedens; John Wemmie; Vincent A Magnotta
Journal:  NMR Biomed       Date:  2019-11-19       Impact factor: 4.044

5.  Moderate Intensity Exercise in Pre-manifest Huntington's Disease: Results of a 6 months Trial.

Authors:  Amro Saad Aldine; Amy Ogilvie; John Wemmie; James Kent; Jordan Schultz; Jeffrey D Long; John Kamholz; Hassan Sajjad; Joel Kline; Emily Shaw; Michelle Voss; Jane S Paulsen; Vincent A Magnotta
Journal:  SVOA Neurol       Date:  2021-02-03

6.  Comparison of T1Rho MRI, Glucose Metabolism, and Amyloid Burden Across the Cognitive Spectrum: A Pilot Study.

Authors:  Laura L Boles Ponto; Vincent A Magnotta; Yusuf Menda; David J Moser; Jacob J Oleson; Emily L Harlynn; Sean D DeVries; John A Wemmie; Susan K Schultz
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2020-04-14       Impact factor: 2.198

7.  Subcortical T1-Rho MRI Abnormalities in Juvenile-Onset Huntington's Disease.

Authors:  Alexander V Tereshchenko; Jordan L Schultz; Ansley J Kunnath; Joel E Bruss; Eric A Epping; Vincent A Magnotta; Peg C Nopoulos
Journal:  Brain Sci       Date:  2020-08-08

Review 8.  Proton Exchange Magnetic Resonance Imaging: Current and Future Applications in Psychiatric Research.

Authors:  Joseph J Shaffer; Merry Mani; Samantha L Schmitz; Jia Xu; Nana Owusu; Dee Wu; Vincent A Magnotta; John A Wemmie
Journal:  Front Psychiatry       Date:  2020-09-24       Impact factor: 4.157

9.  Hippocampal acidity and volume are differentially associated with spatial navigation in older adults.

Authors:  Matthew J Sodoma; Rachel C Cole; Taylor J Sloan; Chase M Hamilton; James D Kent; Vincent A Magnotta; Michelle W Voss
Journal:  Neuroimage       Date:  2021-10-30       Impact factor: 6.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.